Lucid Diagnostics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lucid Diagnostics (LUCD).

Price Target Range — 13 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$4Upside to Avg. PT+814.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 23, 2026	BTIG	Mark Massaro	Maintained	Buy	$3
Aug 27, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$9→$10
Aug 17, 2026	BTIG	Mark Massaro	Maintained	Buy	$3
Jun 8, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$9→$9
May 15, 2026	Maxim Group	Anthony Vendetti	PT Cut	Buy	$3→$2
May 15, 2026	BTIG	Mark Massaro	Maintained	Buy	$3
Apr 9, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$9
Mar 30, 2026	BTIG	Mark Massaro	Maintained	Buy	$3
Mar 26, 2026	Needham	Mike Matson	Maintained	Buy	$3
Dec 10, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$8
Nov 13, 2025	Needham	Mike Matson	Maintained	Buy	$3
Oct 6, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$8
Sep 10, 2025	BTIG	Mark Massaro	Maintained	Buy	$3
Sep 5, 2025	BTIG	Mark Massaro	PT Raise	Buy	$2→$3
Aug 13, 2025	Needham	Mike Matson	Maintained	Buy	$3
Jul 16, 2025	Needham	Mike Matson	Maintained	Buy	$3
Jun 6, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$8
May 15, 2025	Cantor Fitzgerald	Ross Osborn	Maintained	Overweight	$2
May 14, 2025	Needham	Mike Matson	Maintained	Buy	$3
Apr 21, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$7→$8

Analyst Ratings News

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $9.25 to $9.5.

Benzinga Newsdesk

Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says

Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst maintains Buy rating and $2.50 PT.

Priya Nigam

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.

Benzinga Newsdesk

Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case

Lucid Diagnostics reported Q1 revenue miss. Analyst significant expects revenue growth in 2026/27. Raises PT to $9.25.

Priya Nigam

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25

Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $9 to $9.25.

Benzinga Newsdesk

Lucid Diagnostics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Lucid Diagnostics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5

Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25

People Also Watch

People Also Watch

Lucid Diagnostics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Lucid Diagnostics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

PROAscendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5

Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says

PROBTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Lucid Diagnostics Misses On Revenue, But 2026 Growth Outlook Lights Up Bull Case

PROAscendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25

People Also Watch

People Also Watch

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5

PRO
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

PRO
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.25